Calidi Biotherapeutics Business Summary

Calidi Biotherapeutics, Inc. (CLDI) is a clinical-stage immuno-oncology company that generates revenue through strategic collaborations, licensing agreements, and capital raises, with a long-term monetization strategy centered on product sales and royalties. The company operates through two primary technology segments: its universal, "off-the-shelf" cell-based delivery platforms (NeuroNova and SuperNova) and its systemically delivered virotherapy platform (RedTail). These platforms are engineered to protect oncolytic viruses from immune clearance, enabling the targeted delivery of genetic medicines to distal tumor sites for indications such as high-grade gliomas and metastatic solid tumors. Calidi competes directly with immuno-oncology firms like Iovance Biotherapeutics, BioEclipse Therapeutics, and Vor Biopharma, distinguishing itself through its proprietary ability to use allogeneic stem cells and viral envelopes to overcome the limitations of systemic administration and tumor accessibility. Leadership is anchored by CEO Eric Poma, PhD, a biopharma veteran with over 30 years of experience who previously raised $250 million as CEO of Molecular Templates. The executive team includes Chief Scientific Officer and Head of Technical Operations Antonio F. Santidrian, PharmD, PhD, and Chief Medical Officer Guy Travis Clifton, MD, a surgical oncologist with nearly two decades of drug development expertise. Founder and CEO Emeritus Allan Camaisa, a serial entrepreneur with four successful exits to Fortune 1000 companies, remains a key influence as a Director. The company is supported by a board chaired by James Schoeneck and maintains a notable institutional investor base that includes Armistice Capital, Millennium Management, and Vanguard Group.